Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) 88.2 percent of patients receiving pharmacoscopy-guided treatment achieved partial or complete remission, compared to 23.5 percent to their own previous treatment. Further, the median progression-free survival increased four-fold. Retrospectively, pharmacoscopy also predicted the response of AML patients to first-line treatment with 90 percent accuracy. These results show that pharmacoscopy can assist decision-making of the responsible clinicians effectively and thus represent a powerful tool for practical precise and personalized medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news